PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22331954-1	2012	PURPOSE: To investigate whether sunitinib plus docetaxel improves clinical outcomes for patients with human epidermal growth factor receptor 2 (HER2)/neu-negative advanced breast cancer (ABC) versus docetaxel alone.	Sunitinib	32-41	erb-b2 receptor tyrosine kinase 2	Homo sapiens	108-142	
34158245-2	2022	We hypothesized that adding sunitinib, a tyrosine kinase inhibitor with antitumor and antiangiogenic activity, to an anthracycline and taxane regimen would improve pathologic complete response (pCR) rates to a prespecified endpoint of 45% in patients with HER2-negative LABC or IBC.	Sunitinib	28-37	erb-b2 receptor tyrosine kinase 2	Homo sapiens	256-260	
34158245-3	2022	METHODS: We conducted a multicenter, phase II trial of neoadjuvant sunitinib with paclitaxel (S+T) followed by doxorubicin and cyclophosphamide plus G-CSF for patients with HER2-negative LABC or IBC.	Sunitinib	67-76	erb-b2 receptor tyrosine kinase 2	Homo sapiens	173-177	
23022045-0	2012	An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer.	Sunitinib	24-33	erb-b2 receptor tyrosine kinase 2	Homo sapiens	106-110	
23022045-2	2012	METHODS: Patients with unresectable, locally recurrent or metastatic human epidermal growth factor receptor 2 (HER2)+ breast cancer received sunitinib plus docetaxel and trastuzumab.	Sunitinib	141-150	erb-b2 receptor tyrosine kinase 2	Homo sapiens	75-109	
23022045-2	2012	METHODS: Patients with unresectable, locally recurrent or metastatic human epidermal growth factor receptor 2 (HER2)+ breast cancer received sunitinib plus docetaxel and trastuzumab.	Sunitinib	141-150	erb-b2 receptor tyrosine kinase 2	Homo sapiens	111-115	
23022045-14	2012	CONCLUSIONS: Sunitinib combined with docetaxel and trastuzumab had an acceptable toxicity profile and showed preliminary antitumor activity as first-line treatment for metastatic HER2+ breast cancer.	Sunitinib	13-22	erb-b2 receptor tyrosine kinase 2	Homo sapiens	179-183	
22336056-1	2012	BACKGROUND: This exploratory study examined the pharmacokinetics, safety, and antitumor activity of sunitinib plus docetaxel in patients with HER-2-negative advanced breast cancer.	Sunitinib	100-109	erb-b2 receptor tyrosine kinase 2	Homo sapiens	142-147	
35066605-0	2022	The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC.	Sunitinib	53-62	erb-b2 receptor tyrosine kinase 2	Homo sapiens	85-89	
35066605-7	2022	Moreover, sunitinib induced downregulation of HER2 on the target cells" surface, changed the morphology and increased adherence of the target cells.	Sunitinib	10-19	erb-b2 receptor tyrosine kinase 2	Homo sapiens	46-50	
24606768-1	2014	BACKGROUND: This phase II study evaluated the efficacy and safety/tolerability of sunitinib plus trastuzumab in patients with HER2-positive advanced breast cancer (ABC).	Sunitinib	82-91	erb-b2 receptor tyrosine kinase 2	Homo sapiens	126-130	
24606768-15	2014	CONCLUSIONS: Sunitinib plus trastuzumab demonstrated antitumor activity in patients with HER2-positive ABC, particularly those who were treatment-naive or had only received prior adjuvant treatment.	Sunitinib	13-22	erb-b2 receptor tyrosine kinase 2	Homo sapiens	89-93	
24606768-16	2014	Sunitinib plus trastuzumab had acceptable safety and tolerability in patients with HER2-positive ABC who had not received prior anthracycline therapy.	Sunitinib	0-9	erb-b2 receptor tyrosine kinase 2	Homo sapiens	83-87	
22331954-1	2012	PURPOSE: To investigate whether sunitinib plus docetaxel improves clinical outcomes for patients with human epidermal growth factor receptor 2 (HER2)/neu-negative advanced breast cancer (ABC) versus docetaxel alone.	Sunitinib	32-41	erb-b2 receptor tyrosine kinase 2	Homo sapiens	144-148	
20652398-2	2010	The method involves a two-arm open-label (2:1 randomization) multicenter, randomized phase II trial evaluating the efficacy of sunitinib (arm A) versus no therapy (arm B) in patients with HER-2-negative metastatic breast cancer who achieved an objective response to taxane-based chemotherapy.	Sunitinib	127-136	erb-b2 receptor tyrosine kinase 2	Homo sapiens	188-193	
20339913-0	2010	Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.	Sunitinib	30-39	erb-b2 receptor tyrosine kinase 2	Homo sapiens	96-100